Rolipram
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2001 (NCT00011375)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1- Mol. weight
- 275.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL63 ↗
Also known as
- 4-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-pyrrolidinone
- 4-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-pyrrolidinone
- r209130
- rolipram
- rolipram
- rolipram
- rolipram
- rolipramum
- rolipramum
- zk-62711
- zk-62711
- zk-62771
- zk-62771
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05522673 | Phase 1 | Dec 29, 2022 | National Institute of Mental Health (NIMH) |
| NCT02743377 | Phase 1/Phase 2 (Phase 2) | Apr 4, 2018 | National Institute of Mental Health (NIMH) |
| NCT01602900 | Phase 1 | Nov 22, 2011 | GlaxoSmithKline |
| NCT00369798 | Phase 1 | Aug 2, 2006 | National Institute of Mental Health (NIMH) |
| NCT00250172 | Phase 1 | Oct 31, 2005 | National Institute of Mental Health (NIMH) |
| NCT00063297 | Phase 2 | May 1, 2003 | Johnson and Johnson |
| NCT00011375 | Phase 2 | Feb 1, 2001 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 4 | 4 | 2 | 2005 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2011 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2003 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2001 |
4 organizations
Page 1 / 1